keyword
https://read.qxmd.com/read/38652426/antibody-drug-conjugates-in-urological-cancers-a-review-of-the-current-landscape
#1
REVIEW
Aruni Ghose, Patricia Lapitan, Vedika Apte, Adheesh Ghosh, Abhinav Kandala, Sreejana Basu, Jo Parkes, Sayali D Shinde, Stergios Boussios, Anand Sharma, Prantik Das, Nikhil Vasdev, Sara E Rebuzzi, Yüksel Ürün, Ravindran Kanesvaran, Akash Maniam, Giuseppe L Banna
PURPOSE OF REVIEW: Our review delves into the progress across urological malignancies and discusses ongoing challenges and future directions in antibody-drug conjugate (ADC) development, emphasising their transformative potential in cancer care. RECENT FINDINGS: ADCs have advanced from hematologic to solid tumours, notably in breast cancer, and are now pivotal in metastatic urological cancers as both monotherapies and in combination regimens, underscored by the FDA's approval of enfortumab vedotin and sacituzumab govitecan for metastatic urothelial cancer...
April 23, 2024: Current Oncology Reports
https://read.qxmd.com/read/38650416/-robot-assisted-radical-prostatectomy-in-patients-after-transurethral-resection-of-the-prostate
#2
JOURNAL ARTICLE
S Skrupskiy K, B Kolontarev K, M Medvedev R, Yu Pushkar D
Performing a radical treatment of prostate cancer in patients with a history of transurethral resection of the prostate (TURP) is a serious task even for an experienced surgeon, due to the anatomical and topographic changes that occur after endoscopic surgery. The technical possibilities of robotic technologies have great potential for obtaining the best treatment results for this category of patients. In order to review the intra- and postoperative outcomes of robot-assisted radical prostatectomy (RARP) in patients with a history of PCa and TURP, we selected relevant publications in the PubMed and Google Scholar databases for the period from 2008 to 2022...
March 2024: Urologii︠a︡
https://read.qxmd.com/read/38649544/the-role-of-urology-and-radiology-in-prostate-biopsy-current-trends-and-future-perspectives
#3
REVIEW
Benjamin M Mac Curtain, Hugo C Temperley, John A O Kelly, James Ryan, Wanyang Qian, Niall O'Sullivan, Kieran J Breen, Colin J Mc Carthy, Ian Brennan, Niall F Davis
PURPOSE: Prostate biopsy is central to the accurate histological diagnosis of prostate cancer. In current practice, the biopsy procedure can be performed using a transrectal or transperineal route with different technologies available for targeting of lesions within the prostate. Historically, the biopsy procedure was performed solely by urologists, but with the advent of image-guided techniques, the involvement of radiologists in prostate biopsy has become more common. Herein, we discuss the pros, cons and future considerations regarding their ongoing role...
April 22, 2024: World Journal of Urology
https://read.qxmd.com/read/38648995/systematic-review-of-the-efficacy-of-stereotactic-ablative-radiotherapy-for-oligoprogressive-disease-in-metastatic-cancer
#4
REVIEW
Emma Doyle, Angus J Killean, Stephen Harrow, Iain D Phillips
BACKGROUND: Stereotactic Ablative Radiotherapy (SABR) for the treatment of oligometastatic disease can improve survival and delay the requirement for systemic therapy. The benefits of SABR in oligoprogressive disease are less well-defined. Here, we evaluate the available evidence investigating the efficacy of SABR in the treatment of oligoprogressive disease. METHODS: A systematic review was carried out following PRISMA guidelines. Medline and Embase databases were searched using the terms "stereotactic radiotherapy" OR "SABR" OR "Stereotactic Ablative Body Radiotherapy" OR "SBRT" OR "SRT" AND "oligoprogression" in May 2022, June 2023, and February 2024...
April 20, 2024: Radiotherapy and Oncology
https://read.qxmd.com/read/38645812/the-presence-of-cribriform-pattern-in-prostate-biopsy-and-radical-prostatectomy-is-associated-with-negative-postoperative-pathological-features
#5
JOURNAL ARTICLE
Rafal Osiecki, Mieszko Kozikowski, Łukasz Białek, Michał Pyzlak, Jakub Dobruch
INTRODUCTION: Prostate cancer is the second most common male cancer worldwide. Its rising incidence and high overtreatment rate drive the search for new prognostic factors. Histopathological variants, such as cribriform pattern (CP), are associated with poorer oncologic outcome. The aim of this study was to assess the correlation between CP in prostate biopsy and radical prostatectomy (RP) and postoperative pathological features. MATERIAL AND METHODS: In this retrospective, single-centre study we analysed the reviewed medical records of 100 men who underwent minimally invasive RP in the years 2017-2019...
2024: Central European Journal of Urology
https://read.qxmd.com/read/38644318/-a-case-of-adenocarcinoma-of-pancreatic-head-of-liver-disfunction-after-pancreaticoduodenectomy-with-celiac-artery-stenosis-treated-by-urgent-median-arcuate-ligament-release
#6
JOURNAL ARTICLE
Katsunori Matsushita, Shigekazu Yokoyama, Kazuhiko Hashimoto, Yuji Uchiyama, Tsuyoshi Mizuno, Kunihiko Kawai, Teruyuki Kobayashi, Kazuhiro Saso, Takamichi Komori, Kentaro Kishi, Mutsumi Fukunaga
This patient visited our hospital for the purpose of detailed examination of prostate cancer in his seventies. Abdominal contrast-enhanced computed tomography(CT)revealed a low-density mass of 2 cm in the pancreatic head. He was diagnosed with pancreatic cancer. Pancreaticoduodenectomy was performed after 2 courses of gemcitabine and S-1 therapy were performed as neoadjuvant chemotherapy. An intraoperative clamp test of the gastroduodenal artery showed that the pulsation of the common hepatic artery and the proper hepatic artery was weak but sufficient, so the gastroduodenal artery was cut and the operation was completed as planned...
April 2024: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://read.qxmd.com/read/38643440/protein-intake-and-cancer-an-umbrella-review-of-systematic-reviews-for-the-evidence-based-guideline-of-the-german-nutrition-society
#7
REVIEW
Tilman Kühn, Nicole Kalotai, Anna M Amini, Julia Haardt, Andreas Lehmann, Annemarie Schmidt, Anette E Buyken, Sarah Egert, Sabine Ellinger, Anja Kroke, Stefan Lorkowski, Sandrine Louis, Matthias B Schulze, Lukas Schwingshackl, Roswitha Siener, Gabriele I Stangl, Bernhard Watzl, Armin Zittermann, Katharina Nimptsch
PURPOSE: It has been proposed that a higher habitual protein intake may increase cancer risk, possibly via upregulated insulin-like growth factor signalling. Since a systematic evaluation of human studies on protein intake and cancer risk based on a standardised assessment of systematic reviews (SRs) is lacking, we carried out an umbrella review of SRs on protein intake in relation to risks of different types of cancer. METHODS: Following a pre-specified protocol (PROSPERO: CRD42018082395), we retrieved SRs on protein intake and cancer risk published before January 22th 2024, and assessed the methodological quality and outcome-specific certainty of the evidence using a modified version of AMSTAR 2 and NutriGrade, respectively...
April 21, 2024: European Journal of Nutrition
https://read.qxmd.com/read/38643347/single-port-robot-assisted-radical-prostatectomy
#8
REVIEW
Nicolas A Soputro, Jihad Kaouk
PURPOSE: To provide a comprehensive update on the different techniques and outcomes of contemporary Single-Port (SP) Robotic Radical Prostatectomy (RARP) approaches. METHODS: A literature review was performed to identify cohort studies that have utilized the purpose-built SP robotic platform (Intuitive Surgical Inc., Sunnyvale, California) for RARP. All published approaches of SP-RARP were included in our review. Baseline clinical, perioperative, and postoperative oncological and functional outcomes were collected from the included studies...
April 20, 2024: World Journal of Urology
https://read.qxmd.com/read/38643307/prostatectomy-in-oligometastatic-prostate-cancer-a-call-for-high-quality-evidence
#9
REVIEW
Tanya Dorff, Sheetal R Kashid, Vedang Murthy, Riccardo Lombardo, Cosimo De Nunzio
The systematic review by Saouli et al. investigates the role of radical prostatectomy (RP) in managing oligometastatic prostate cancer (omPCa) [1]. They analyzed the existing literature to assess the oncological and functional outcomes of RP for these patients. RP is feasible and has an acceptable risk of complications. However, the lack of consensus on the definitions of omPCa and the low-quality evidence of the available comparative and retrospective studies, RP in omPCa should not be recommended outside of clinical trials...
April 20, 2024: Prostate Cancer and Prostatic Diseases
https://read.qxmd.com/read/38642309/assessment-of-structural-and-activity-related-contributions-of-various-pim-1-kinase-inhibitors-in-the-treatment-of-leukemia-and-prostate-cancer
#10
REVIEW
Anushka Sharma, Rahul Dubey, Vikas Asati, Gurkaran Singh Baweja, Shankar Gupta, Vivek Asati
One of the most perilous illnesses in the world is cancer. The cancer may be associated with the mutation of different genes inside the body. The PIM kinase, also known as the serine/threonine kinase, plays a critical role in the biology of different kinds of cancer. They are widely distributed and associated with several biological processes, including cell division, proliferation, and death. Aberration of PIM-1 kinase is found in varieties of cancer. Prostate cancer and leukemia can both be effectively treated with PIM-1 kinase inhibitors...
April 20, 2024: Molecular Diversity
https://read.qxmd.com/read/38642173/psychosocial-factors-associated-with-cognitive-function-in-prostate-cancer-survivors-on-hormonal-treatments-a-systematic-review
#11
REVIEW
Lorna Pembroke, Kerry A Sherman, Heather Francis, Haryana M Dhillon, Howard Gurney, David Gillatt
Hormonal treatments (HT) for prostate cancer (e.g., androgen deprivation therapy) yield clinical and survival benefits, yet adverse cognitive changes may be a side effect. Since psychosocial factors are largely modifiable, interventions targeting these factors may help mitigate these adverse cognitive effects. This systematic review aimed to identify a range of psychosocial factors associated with cognitive function in individuals with prostate cancer undergoing HT and to determine whether these factors mitigate or exacerbate this effect...
April 20, 2024: Neuropsychology Review
https://read.qxmd.com/read/38639959/-a-review-on-the-application-of-image-fusion-technology-in-prostate-cancer-radiotherapy-based-on-gold-fiducial-biomarker
#12
JOURNAL ARTICLE
Jian-Cheng Zhao, Long Tian
Image fusion technology had been widely applied in image guided radiotherapy (IGRT) for prostate cancer (PCa) based on the gold fiducial mark (GFM). Image fusion technology included the fusion of CT image, magnetic resonance image, and ultrasound image internally or externally. The application of image fusion technology had improved the identification accuracy of GFM and was helpful for the plan design of PCa radiotherapy. This article provided a systematic review of the application of fusion of various medical images in PCa IGRT in recent years...
December 2023: Zhonghua Nan Ke Xue, National Journal of Andrology
https://read.qxmd.com/read/38639585/advances-in-tumor-management-harnessing-the-potential-of-histotripsy
#13
REVIEW
Yash Verma, Arosh S Perera Molligoda Arachchige
Tissue ablation techniques have long been used in clinical settings to treat various oncologic diseases. However, many of these techniques are invasive and can cause substantial adverse effects. Histotripsy is a noninvasive, nonionizing, nonthermal tissue ablation technique that has the potential to replace surgical interventions in various clinical settings. Histotripsy works by delivering high-intensity focused ultrasound waves to target tissue. These waves create cavitation bubbles within tissues that rapidly expand and collapse, thereby mechanically fractionating the tissue into acellular debris that is subsequently absorbed by the body's immune system...
May 2024: Radiology. Imaging cancer
https://read.qxmd.com/read/38639402/a-practical-guide-for-the-use-of-apalutamide-for-non-metastatic-castration-resistant-prostate-cancer-in-australia
#14
REVIEW
Gavin Marx, Simon Chowdhury, Laurence Krieger, Elizabeth Hovey, Jeremy Shapiro, Ben Tran, Thean Hsiang Tan, Siobhan Ng, Henry H Woo
Studies of patients with castrate-resistant prostate cancer at high risk of developing overt metastases but with no current evidence of evaluable disease on computed tomography or bone scan non-metastatic castrate-resistant prostrate cancer have demonstrated increased metastasis-free survival and overall survival following treatment with the next-generation oral anti-androgen apalutamide (in addition to therapies that aim to lower testosterone to castrate levels) or luteinizing hormone-releasing hormone antagonist or surgical castration...
April 19, 2024: Asia-Pacific Journal of Clinical Oncology
https://read.qxmd.com/read/38639331/the-role-of-extracellular-vesicles-in-the-treatment-of-prostate-cancer
#15
REVIEW
Cong Hu, Qi Chen, Tianyang Wu, Xinxing Du, Yanhao Dong, Zehong Peng, Wei Xue, Vijaya Sunkara, Yoon-Kyoung Cho, Liang Dong
Prostate cancer (PCa) has become a public health concern in elderly men due to an ever-increasing number of estimated cases. Unfortunately, the available treatments are unsatisfactory because of a lack of a durable response, especially in advanced disease states. Extracellular vesicles (EVs) are lipid-bilayer encircled nanoscale vesicles that carry numerous biomolecules (e.g., nucleic acids, proteins, and lipids), mediating the transfer of information. The past decade has witnessed a wide range of EV applications in both diagnostics and therapeutics...
April 19, 2024: Small
https://read.qxmd.com/read/38637140/a-systematic-review-on-the-diagnostic-value-of-fibroblast-activation-protein-inhibitor-pet-ct-in-genitourinary-cancers
#16
JOURNAL ARTICLE
Marinus J Hagens, Pim J van Leeuwen, Maurits Wondergem, Thierry N Boellaard, Francesco Sanguedolce, Daniela E Oprea-Lager, Axel Bex, André N Vis, Henk G van der Poel, Laura S Mertens
In contemporary oncologic diagnostics, molecular imaging modalities are pivotal for precise local and metastatic staging. Recent studies identified fibroblast activation protein as a promising target for molecular imaging across various malignancies. Therefore, we aimed to systematically evaluate the current literature on the utility of fibroblast activation protein inhibitor (FAPI) PET/CT for staging patients with genitourinary malignancies. Methods: A systematic Embase and Medline search was conducted, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) process, on August 1, 2023...
April 18, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38635890/parp-ish-gaps-in-molecular-understanding-and-clinical-trials-targeting-parp-exacerbate-racial-disparities-in-prostate-cancer
#17
JOURNAL ARTICLE
Moriah Cunningham, Matthew J Schiewer
PARP is a nuclear enzyme with a major function in the DNA damage response. PARP inhibitors (PARPi) have been developed for treating tumors harboring homologous recombination repair (HRR) defects that lead to a dependency on PARP. There are currently three PARPi approved for use in advanced prostate cancer (PCa), and several others are in clinical trials for this disease. Recent clinical trial results have reported differential efficacy based on the specific PARPi utilized as well as patient race. There is a racial disparity in PCa, where African American (AA) males are twice as likely to develop and die from the disease compared to European American (EA) males...
April 18, 2024: Cancer Research
https://read.qxmd.com/read/38635829/geraniol-and-citral-recent-developments-in-their-anticancer-credentials-opening-new-vistas-in-complementary-cancer-therapy
#18
REVIEW
Gauri Srivastava, Esha Mukherjee, Ruchika Mittal, Deepak Ganjewala
About 10 million people are diagnosed with cancer each year. Globally, it is the second leading cause of death after heart disease, and by 2035, the death toll could reach 14.6 million. Several drugs and treatments are available to treat cancer, but survival rates remain low. Many studies in recent years have shown that plant-derived monoterpenes, particularly geraniol and citral, are effective against various cancers, including breast, liver, melanoma, endometrial, colon, prostate, and skin cancers. This trend has opened new possibilities for the development of new therapeutics or adjuvants in the field of cancer therapy...
April 19, 2024: Zeitschrift Für Naturforschung. C, A Journal of Biosciences
https://read.qxmd.com/read/38633829/the-impact-of-pre-biopsy-mri-and-additional-testing-on-prostate-cancer-screening-outcomes-a-rapid-review
#19
REVIEW
Abel Tesfai, Natalia Norori, Thomas A Harding, Yui Hang Wong, Matthew David Hobbs
OBJECTIVE: This work aims to examine the latest evidence on the impact of pre-biopsy MRI, in addition to prostate-specific antigen (PSA) testing, on health outcomes and quality of life. METHODS: We conducted a literature search including PubMed and Cochrane Central Register of Controlled Trials (CENTRAL) databases, with a limited scan of (i) guidelines and (ii) references from trial reports, from January 2005 to 25th January 2023. Two independent reviewers selected randomised controlled trials (RCT) and cohort studies which met our inclusion criteria...
April 2024: BJUI compass
https://read.qxmd.com/read/38633827/the-potential-role-of-precision-medicine-to-alleviate-racial-disparities-in-prostate-bladder-and-renal-urological-cancer-care
#20
REVIEW
Kunal K Sindhu, Zachary Dovey, Marcher Thompson, Anthony D Nehlsen, Karin A Skalina, Beata Malachowska, Shaakir Hasan, Chandan Guha, Justin Tang, Lucas Resende Salgado
BACKGROUND: Racial disparities in oncological outcomes resulting from differences in social determinants of health (SDOH) and tumour biology are well described in prostate cancer (PCa) but similar inequities exist in bladder (BCa) and renal cancers (RCCs). Precision medicine (PM) aims to provide personalized treatment based on individual patient characteristics and has the potential to reduce these inequities in GU cancers. OBJECTIVE: This article aims to review the current evidence outlining racial disparities in GU cancers and explore studies demonstrating improved oncological outcomes when PM is applied to racially diverse patient populations...
April 2024: BJUI compass
keyword
keyword
63533
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.